Lexaria Bioscience Corp (NASDAQ:LEXX) stock climbed 3.4% following the announcement that the company has achieved a key milestone in its Phase 1b glucagon-like peptide-1 (GLP-1) study in Australia.
The drug delivery platform developer confirmed that its Contract Research Organization (CRO) reached the last patient last visit (LPLV) milestone in the GLP-1-H24-4 trial, marking the completion of all patient dosing and clinical testing. The company is now moving into the sample and data analysis stage.
“We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our study,” said John Docherty, Lexaria’s President and CSO. The company expects to deliver final study results by late 2025.
Earlier, Lexaria released partial 8-week interim data, which were described as positive and aligned with the study’s primary endpoint. The interim results reportedly indicated favorable safety and tolerability, particularly showing fewer gastrointestinal adverse events compared with the Rybelsus® control arm.
The company remains blinded to the full study data while the CRO processes and analyzes the thousands of samples collected during the trial.
Lexaria Bioscience stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.